The potential for abuse of stimulants in chronically sleep-restricted populations

Sleep Deprivation, Stimulant Medications, and Cognition

Volumn , Issue , 2012, Pages 122-135

  Childs, Emma ^a   de Wit, Harriet ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907848238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511783005.011     Document Type: Chapter

References (92)

1. Comprehensive Drug Abuse Prevention and Control Act, Pub. L. No. 91-513, 84, Stat. 1236, October 27, 1970.
2. Substance Abuse and Mental Health Services Administration. The DASIS Report - Primary Methamphetamine/Amphetamine Admissions to Substance Abuse Treatment: 2005. Rockville, MD: Office of Applied Studies; February 7, 2008.
3. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. NSDUH Series H-36, HHS Publication No. SMA 09-4434. Rockville, MD: Office of Applied Studies; 2009.
4. Food and Drug Administration Subcommittee on Guidelines for Abuse Liability Assessment. Draft Guidelines for Abuse Liability Assessment. Washington, DC: Food and Drug Administration; 1990.
5. Drug Enforcement Administration. Drugs of Abuse. US Department of Justice; 2005.
6. Robbins TW, Everitt BJ. Drug addiction: bad habits add up. Nature 1999; 398: 567-70.
7. Eshleman AJ, Henningsen RA, Neve KA, et al. Release of dopamine via the human transporter. Mol Pharmacol 1994; 45: 312-16.
8. Lajtha A, Sershen H. Heterogeneity of reward mechanisms. Neurochem Res 2010; 35: 851-67.
9. Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009; 105 (Suppl 1): S14-25.
10. Griffiths R, Bigelow GE, Henningfield JE. Similarities in animal and human drug-taking behavior. In: Mello NK, editor. Advances in Substance Abuse. Greenwich, CT: JAI Press; 1980: 1-90.
11. Schuster CR, Johanson CE. Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert FC, Balster RL, editors. Transduction Mechanisms of Drug Stimuli. Berlin: Springer; 1988: 161-75.
12. Preston KL. Drug discrimination methods in human drug abuse liability evaluation. Br J Addict 1991; 86: 1587-94.
13. McNair DLM, Droppleman L. Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1971.
14. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12: 245-58.
15. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: diazepam. Psychopharmacology (Berl) 1980; 71: 269-73.
16. Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 2000; 406: 1-13.
17. American Medical Association. Dependence on amphetamines and other stimulant drugs. JAMA, 1966; 197: 193-7.
18. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001; 68: 611-27.
19. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12: 245-58.
20. Cole JO, Pope HG, Jr, LaBrie R, et al. Assessing the subjective effects of stimulants in casual users: a methodology and preliminary results. Clin Pharmacol Ther 1978; 24: 243-52.
21. de Wit H, Uhlenhuth EH, Johanson CE. Drug preference in normal volunteers: effects of age and time of day. Psychopharmacology (Berl) 1985; 87: 186-93.
22. de Wit H, Uhlenhuth EH, Johanson CE. Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 1986; 16: 341-60.
23. de Wit H, Uhlenhuth EH, Johanson CE. The reinforcing properties of amphetamine in overweight subjects and subjects with depression. Clin Pharmacol Ther 1987; 42: 127-36.
24. Zacny JP, de Wit H. Effects of food deprivation on subjective responses to d-amphetamine in humans. Pharmacol Biochem Behav 1989; 34: 791-5.
25. Angrist B, Corwin J, Bartlik B, et al. Early pharmacokinetics and clinical effects of oral Damphetamine in normal subjects. Biol Psychiatry 1987; 22: 1357-68.
26. Bigelow GE, Griffiths RR, Liebson I, et al. Double-blind evaluation of reinforcing and anorectic actions of weight control medications: interaction of pharmacological and behavioral treatments. Arch Gen Psychiatry 1980; 37: 1118-23.
27. Johanson CE, Kilgore K, Uhlenhuth EH. Assessment of dependence potential of drugs in humans using multiple indices. Psychopharmacology (Berl) 1983; 81: 144-9.
28. Sevak RJ, Stoops WW, Hays LR, Rush CR. (2009) Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 2009; 328: 1007-18.
29. Chait LD, Uhlenhuth EH, Johanson CE. The discriminative stimulus and subjective effects of damphetamine, phenmetrazine and fenfluramine in humans. Psychopharmacology (Berl) 1986; 89: 301-6.
30. Chait LD, Uhlenhuth EH, Johanson CE. Individual differences in the discriminative stimulus effects of d-amphetamine in humans. Drug Develop Res 1989; 16: 451-60.
31. Woolverton WL. Discriminative stimulus effects of cocaine. NIDA Res Monogr 1991; 116: 61-74.
32. Fischman MW, Schuster CR, Resnekov L, et al. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry 1976; 33: 983-9.
33. Gabbay FH. Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol 2003; 11: 91-101.
34. Uhlenhuth EH, Johanson CE, Kilgore K, et al. Drug preference and mood in humans: preference for d-amphetamine and subject characteristics. Psychopharmacology (Berl) 1981; 74: 191-4.
35. Silverman K, Kirby KC, Griffiths RR. Modulation of drug reinforcement by behavioral requirements following drug ingestion. Psychopharmacology (Berl) 1994; 114: 243-7.
36. Schuster CR. Testing and abuse liability of drugs in humans. In: Fischman MW, Mello NK, editors. Testing for Abuse Liability of Drugs in Humans: NIDA Research Monograph, vol 92. Washington, DC: US Government Printing Office; 1989: 1-6.
37. Berman SM, Kuczenski R, McCracken JT, et al. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 2009; 14: 123-42.
38. Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep 1993; 16: 306-17.
39. Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 2008; 27: 229-35.
40. Clemens KJ, Cornish JL, Hunt GE, et al. Intravenous methamphetamine self-administration in rats: effects of intravenous or intraperitoneal MDMA co-administration. Pharmacol Biochem Behav 2006; 85: 454-63.
41. Czoty PW, Makriyannis A, Bergman J. Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology (Berl) 2004; 175: 170-8.
42. Newton TF, De La Garza R, 2nd, Kalechstein AD, et al. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol Biochem Behav 2005; 82: 90-7.
43. Hart CL, Haney M, Foltin RW, et al. Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology (Berl) 2002; 164: 376-84.
44. Lamb RJ, Henningfield JE. Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. J Exp Anal Behav 1994; 61: 169-80.
45. Johanson CE, Lundahl LH, Lockhart N, et al. Intravenous cocaine discrimination in humans. Exp Clin Psychopharmacol 2006; 14: 99-108.
46. Hart CL, Ward AS, Haney M, et al. Methamphetamine self-administration by humans. Psychopharmacology (Berl) 2001; 157: 75-81.
47. McGregor C, Srisurapanont M, Jittiwutikarn J, et al. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100: 1320-9.
48. Volkow ND, Wang GJ, Fowler JS, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999; 65: PL7-12.
49. Parran TV, Jr, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 1991; 151: 781-3.
50. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002; 14: 219-23.
51. Nielsen JA, Duda NJ, Mokler DJ, et al. Selfadministration of central stimulants by rats: a comparison of the effects of d-amphetamine, methylphenidate and McNeil 4612. Pharmacol Biochem Behav 1984; 20: 227-32.
52. Bergman J, Madras BK, Johnson SE, et al. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989; 251: 150-5.
53. Wood DM, Emmett-Oglesby MW. Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology (Berl) 1988; 95: 364-8.
54. Huang JT, Ho BT. Discriminative stimulus properties of d-amphetamine and related compounds in rats. Pharmacol Biochem Behav 1974; 2: 669-73.
55. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14: 53-60.
56. Rush CR, Kollins SH, Pazzaglia PJ. Discriminativestimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 1998; 6: 32-44.
57. Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol 2001; 9: 59-73.
58. Aman MG, Vamos M, Werry JS. Effects of methylphenidate in normal adults with reference to drug action in hyperactivity. Aust N Z J Psychiatry 1984; 18: 86-8.
59. Rush CR, Essman WD, Simpson CA, et al. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 2001; 21: 273-86.
60. Stoops WW, Lile JA, Fillmore MT, et al. Reinforcing effects of methylphenidate: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 2005; 177: 349-55.
61. Roehrs T, Papineau K, Rosenthal L, et al. Sleepiness and the reinforcing and subjective effects of methylphenidate. Exp Clin Psychopharmacol 1999; 7: 145-50.
62. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998; 6: 367-74.
63. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456-63.
64. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001; 68: 611-27.
65. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J Atten Disord 2002; 6(Suppl 1): S65-71.
66. Saper CB, Scammell TE. Modafinil: a drug in search of a mechanism. Sleep 2004; 27: 11-2.
67. Duteil J, Rambert FA, Pessonnier J, et al. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 1990; 180: 49-58.
68. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436-7.
69. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21: 1787-94.
70. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA, 2009; 301: 1148-54.
71. Myrick H, Malcolm R, Taylor B, et al. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Ann Clin Psychiatry 2004; 16: 101-9.
72. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554-66.
73. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, et al. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 2002; 161: 387-95.
74. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996; 126: 286-92.
75. Paterson NE, Fedolak A, Olivier B, et al. Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wakepromoting agent modafinil in rodents. Pharmacol Biochem Behav 2010; 95: 449-56.
76. Makris AP, Rush CR, Frederich RC, et al. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Exp Clin Psychopharmacol 2007; 15: 123-33.
77. Rush CR, Kelly TH, Hays LR, et al. Discriminativestimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend 2002; 67: 311-22.
78. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23: 149-56.
79. Bogan RK. Armodafinil in the treatment of excessive sleepiness. Expert Opin Pharmacother 2010; 11: 993-1002.
80. Langer DH, Sweeney KP, Bartenbach DE, et al. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986; 17: 213-27.
81. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol 1996; 34: 119-29.
82. Ribeiro JA, Sebastião AM. Caffeine and adenosine. J Alzheimers Dis 2010; 20(Suppl 1): S3-15.
83. Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol 2005; 16: 63-77
84. Atkinson J, Enslen M. Self-administration of caffeine by the rat. Arzneimittelforschung 1976; 26: 2059-61.
85. Griffiths RR, Mumford GK. Caffeine - a drug of abuse? In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995: 1699-713.
86. Childs E, de Wit H. Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 2006; 185: 514-23.
87. Wesensten NJ, Killgore WD, Balkin TJ. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005; 14: 255-66.
88. Smith A, Sutherland D, Christopher G. Effects of repeated doses of caffeine on mood and performance of alert and fatigued volunteers. J Psychopharmacol 2005; 19: 620-6.
89. Evans SM, Griffiths RR. Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther 1999; 289: 285-94.
90. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
91. James JE. Does caffeine enhance or merely restore degraded psychomotor performance? Neuropsychobiology 1994; 30: 124-5.
92. Auger RR, Goodman SH, Silber MH, et al. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 2005; 28: 667-72.